Biosensors and Nanotheranostics

Bionanotechnology, Drug Delivery, Therapeutics | online ISSN 3064-7789
175
Citations
127.7k
Views
108
Articles
Your new experience awaits. Try the new design now and help us make it even better
Switch to the new experience
Figures and Tables
REVIEWS   (Open Access)

Exploring the role of GLP-1 Receptor Agonists in managing Women's Longevity Through Muscle, Bone, and Brain Health

Amena Khatun Manica1*, Shahadat Hossain2

+ Author Affiliations

Biosensors and Nanotheranostics 4 (1) 1-8 https://doi.org/10.25163/biosciences.4110517

Submitted: 16 August 2025 Revised: 02 October 2025  Published: 11 October 2025 


Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists, initially created for obesity and type 2 diabetes, are highly recognized for their broader health benefits. Among women, such therapies can significantly impact muscular strength, brain health, and bone density, and these also shape the functional longevity beyond traditional metabolic results. The current paper reached findings from the current clinical trials, expert guidelines, previous studies, and from meta-analysis evaluating the GLP-1 receptor agonists’ response towards musculoskeletal, neurocognitive, and metabolic health with a specific focus on the sex specific response among women and outcomes of longevity. The study findings have disclosed that these evidences show GLP-1 therapies are helpful for insulin sensitivity, increase bone turnover, preserve the integrity of muscles with exercise, and also exert neuroprotective effects. Furthermore, women validate different responses impacted by hormonal status, and the therapy with multidimensional potential highlights the importance of integrated and tailored interventions and lifestyle strategies. The action of GLP-1 receptor is promising to extend the functional longevity among women by preserving the musculoskeletal and cognitive health. However, limited sex-specific long-term and weight loss-linked lean mass reduction data demand combined therapy with nutrition, exercise, and individualized monitoring for optimizing the outcomes and reducing risks. GLP-1 receptor agonists provide multidimensional benefits for women, supporting muscle, bone, and brain health alongside metabolic control. Their potential to extend functional longevity is maximized when paired with exercise, balanced nutrition, and personalized monitoring, particularly considering hormonal influences, enabling a holistic, sex-specific approach to optimize outcomes and mitigate associated risks.Keywords: GLP-1 Receptor Agonists, Women’s Health, Functional Longevity, Muscle and Bone Health,Cognitive Resilience

1. Introduction

Glucagon-like peptide-1 (GLP-1) receptor agonists have gradually emerged as one of the more consequential therapeutic developments in contemporary metabolic medicine, largely because of how broadly their effects appear to extend (Wang et al., 2023). Initially developed to address obesity and type 2 diabetes mellitus, these agents were evaluated primarily for their ability to improve glycemic regulation and promote weight loss (Ramracheya et al., 2018). Yet, as evidence accumulated, it became increasingly difficult to view GLP-1 agonists as acting solely within the narrow confines of glucose control. Their physiological reach, it seems, is far wider (Lee & Jun, 2016).

At a basic level, GLP-1 is an incretin hormone secreted by intestinal L-cells in response to nutrient intake (Nauck & Meier, 2018). Its receptors, however, are not restricted to the pancreas. They are distributed across multiple organ systems, including the brain, skeletal muscle, adipose tissue, and bone. Through these pathways, GLP-1 signaling enhances insulin secretion, suppresses glucagon release, delays gastric emptying, and influences satiety and appetite regulation (Lee & Jun, 2016). These mechanisms help explain the well-established benefits observed in diabetes and obesity management. What has drawn more recent attention is the implication that such widespread receptor distribution may position GLP-1 agonists as modulators of broader processes relevant to women’s health and aging .

Maintaining skeletal muscle mass is particularly important for women, especially in the context of weight loss interventions and advancing age, where declines in muscle integrity can undermine functional independence and quality of life (Wang et al., 2023). Preclinical studies suggest that GLP-1 receptor agonists enhance insulin sensitivity within muscle tissue while simultaneously dampening pro-inflammatory signaling pathways, effects that may offer some protection against muscle catabolism (Kong et al., 2023). There is also evidence pointing toward improvements in mitochondrial efficiency, raising the possibility that GLP-1 therapies may support energy balance and endurance at the cellular level (Macedo et al., 2020).Clinical observations, however, complicate this optimistic picture. Although GLP-1 agonists reliably induce fat loss, they are frequently accompanied by reductions in lean mass. In some cases, skeletal muscle accounts for as much as 15–30% of the total weight lost, an outcome that is particularly concerning for women already vulnerable to sarcopenia (Ahmed et al., 2023). These findings have prompted professional bodies to emphasize the importance of pairing pharmacological therapy with resistance training and sufficient protein intake. When integrated thoughtfully, GLP-1 treatment may therefore reshape metabolic health while still allowing room to preserve muscle strength and long-term mobility (Vilarrasa et al., 2024).

 

Bone health represents another domain in which GLP-1 signaling appears to play a meaningful, if still evolving, role (Mabilleau et al., 2018). Osteoporosis and fracture risk disproportionately affect women, particularly after menopause, making skeletal preservation a central concern in healthy aging. Experimental studies have identified GLP-1 receptor expression in bone-related cells, suggesting that these agents may exert direct effects on bone remodeling processes (Meng et al., 2016). Preclinical findings indicate that GLP-1 agonists can stimulate bone formation while inhibiting resorption, thereby shifting the balance toward skeletal maintenance (Xie et al., 2021).Clinical data, though more limited, are cautiously encouraging. Modest improvements in bone turnover markers and bone mineral density—particularly at vulnerable sites such as the lumbar spine and femoral neck—have been reported in patients receiving GLP-1 therapy (Tanday et al., 2022). Importantly, despite the weight loss typically associated with these agents, fracture risk does not appear to increase significantly. This suggests that GLP-1 agonists may offer a rare combination of metabolic benefit without the expected skeletal penalty, especially when accompanied by adequate calcium and vitamin D intake and regular physical activity (Singh & Singh, 2022).

 

Beyond musculoskeletal outcomes, cognitive health has emerged as a further area of interest. Neurodegenerative conditions such as Alzheimer’s disease disproportionately affect women, and strategies that support cognitive resilience are increasingly emphasized in aging research (Mahapatra et al., 2022). GLP-1 analogs act centrally to influence appetite and emotional eating behaviors, with secondary benefits for mood and perceived quality of life. More intriguingly, accumulating evidence points to potential neuroprotective effects. GLP-1 signaling has been linked to reductions in oxidative stress, modulation of neuroinflammation, and interference with amyloid-related pathways implicated in cognitive decline (Behl et al., 2020; Kopp et al., 2022). These mechanisms suggest that GLP-1 therapies may contribute not only to metabolic control but also to the preservation of cognitive function over time.It is also increasingly clear that responses to GLP-1 receptor agonists are not uniform across sexes. Women may exhibit distinct therapeutic profiles, shaped in part by hormonal influences such as estrogen, which can modify GLP-1 activity and downstream metabolic effects (Richard et al., 2016). These differences have implications for fat distribution, energy regulation, and possibly reproductive health, underscoring the importance of sex-specific analyses in both research and clinical practice (Rentzeperi et al., 2022). The intersection of endocrinology, metabolism, and reproductive health further highlights the need for tailored treatment strategies rather than one-size-fits-all approaches (Konan et al., 2023).Against this background, the present study seeks to examine how GLP-1 receptor agonists influence muscle integrity and strength preservation among women undergoing pharmacological weight loss therapy. In parallel, it aims to assess their effects on bone density, turnover, and fracture risk, with an emphasis on long-term musculoskeletal health. By focusing on these outcomes together, the study attempts to clarify whether GLP-1 therapies can support not only weight reduction but also the broader goals of functional longevity and healthy aging in women.

2. GLP-1 Receptor Agonists and Functional Longevity in Women

 

2.1 GLP-1 and Women’s Health Perspective

GLP-1 receptor agonists were initially developed with a fairly focused clinical intention: to improve glycemic control and support weight reduction among individuals living with type 2 diabetes and obesity. Over time, however, this framing has proven increasingly difficult to maintain. As research has expanded, the physiological reach of GLP-1 signaling has appeared less confined to these original endpoints and more diffusely involved in processes related to energy regulation, inflammatory balance, and tissue maintenance. Taken together, these effects suggest a broader relevance to functional longevity, a consideration that may be especially important when viewed through the lens of women’s health (Barrera et al., 2011; Nauck & Meier, 2018).

At the biological level, GLP-1 enhances glucose-dependent insulin secretion, suppresses glucagon release, and contributes to central satiety signaling, thereby supporting overall energy homeostasis (Ramracheya et al., 2018). Yet this description, while accurate, only partially captures the complexity of GLP-1 action. What complicates the picture—and arguably makes it more relevant to women’s health—is the extensive distribution of GLP-1 receptors beyond pancreatic tissue. These receptors are expressed in skeletal muscle, bone, and multiple regions of the central nervous system, raising the possibility that GLP-1–based therapies may influence age-related health trajectories rather than simply modify metabolic indices in isolation (Wang et al., 2023).

For women, whose aging processes are often shaped by intersecting vulnerabilities such as progressive muscle loss, declining bone integrity, and increased risk of cognitive impairment, these pleiotropic effects take on particular significance. There is growing recognition that GLP-1 receptor agonists may reduce cardiovascular and renal complications while also lowering overall mortality among metabolically vulnerable populations. Such outcomes, while indirect, are closely tied to long-term functional independence and quality of life (Singh & Singh, 2022). At the same time, sex-specific evidence remains comparatively limited. Important questions persist regarding how women uniquely respond to prolonged GLP-1 exposure, especially across different stages of hormonal transition (Rentzeperi et al., 2022). This gap highlights the need for research frameworks that situate GLP-1 therapy within the broader context of women’s endocrine physiology and aging biology, rather than treating sex as a secondary or incidental variable (Konan et al., 2023).

2.2 Muscle Strength

Preservation of skeletal muscle mass is a central determinant of functional longevity in women, particularly during periods of weight loss and across menopausal transitions. GLP-1 receptor agonists appear to improve insulin sensitivity within muscle tissue while simultaneously dampening inflammatory signaling, mechanisms that may help limit muscle degradation over time (Mabilleau et al., 2018). Experimental evidence further suggests that GLP-1 signaling enhances mitochondrial efficiency, a process that may protect muscle fibers from age-related and inactivity-associated decline (Macedo et al., 2020).

Clinical outcomes, however, present a more nuanced and sometimes conflicting picture. Weight loss induced by GLP-1 therapy is frequently accompanied by reductions in lean body mass, with skeletal muscle accounting for approximately 15–30% of total weight lost in certain cases (Ahmed et al., 2023). If left unaddressed, such losses may compromise strength, balance, and long-term functional capacity. Increasingly, evidence supports the view that these risks can be mitigated when pharmacological treatment is paired with resistance training and adequate nutritional support, including sufficient protein intake (Richard et al., 2016; Singh & Singh, 2022).

For perimenopausal and postmenopausal women, these integrative strategies may be particularly important. Muscle strength is closely linked to independence, mobility, and protection against frailty, making it a critical determinant of quality of life with advancing age (Love et al., 2020). Improvements in insulin sensitivity and mitochondrial function within muscle tissue have also been documented in broader metabolic studies, reinforcing the notion that muscle health may benefit indirectly from GLP-1–mediated metabolic improvements (Reed et al., 2021; Wu et al., 2022). When supported appropriately, GLP-1 therapy may therefore contribute to muscle preservation rather than undermine it.

2.3 Bone Formation and Resorption

Bone health represents another physiological domain in which GLP-1 receptor agonists may exert clinically meaningful effects. GLP-1 receptors have been identified in osteoblasts, suggesting a direct role in bone remodeling processes (Meng et al., 2016). Preclinical studies indicate that GLP-1 signaling may stimulate bone formation while simultaneously limiting resorption, thereby shifting the balance toward skeletal preservation (Xie et al., 2021).

Human data, although still limited, suggest modest improvements in bone turnover markers and bone mineral density, particularly at sites vulnerable to fracture such as the lumbar spine and femoral neck (Tanday et al., 2022). Importantly, despite longstanding concerns that weight loss might exacerbate bone loss, current evidence does not indicate a significant increase in fracture risk associated with GLP-1 therapy (Mabilleau et al., 2018; Schiellerup et al., 2019). These findings suggest that, when combined with adequate calcium and vitamin D intake as well as regular physical activity, GLP-1 agonists may support metabolic improvement without compromising skeletal integrity.

2.4 Sex Differences and Response

Although GLP-1 receptor agonists demonstrate efficacy across sexes, emerging evidence indicates that women may respond differently to these therapies. Estrogen appears to modulate GLP-1 signaling pathways, influencing appetite regulation, fat distribution, and reward-related neural circuits (Richard et al., 2016). Such hormonal interactions may help explain the variability observed in metabolic outcomes and side-effect profiles among women receiving GLP-1 treatment (Rentzeperi et al., 2022).

Understanding these sex-specific dynamics is essential for optimizing therapeutic strategies. Women’s metabolic health is closely intertwined with reproductive and endocrine function, rendering uniform treatment approaches potentially insufficient across different life stages (Konan et al., 2023). Tailored dosing, careful monitoring, and thoughtful integration of lifestyle interventions may therefore be required to maximize therapeutic benefit while minimizing unintended consequences during long-term therapy.

2.5 Appetite, Mood, and Cognitive Resilience

Beyond their peripheral metabolic effects, GLP-1 receptor agonists exert significant actions within the central nervous system. By activating receptors in the hypothalamus and brainstem, these agents suppress appetite, reduce food cravings, and slow gastric emptying, leading to sustained reductions in caloric intake (Rentzeperi et al., 2022). Importantly, appetite regulation often extends beyond weight loss alone, with reported improvements in eating behaviors and reductions in emotionally driven eating patterns.

Psychological outcomes are increasingly recognized as integral to the GLP-1 therapeutic profile. Clinical and observational data suggest improvements in mood, quality of life, and emotional regulation—effects that may be particularly relevant for women, who experience higher lifetime risks of depression and eating-related disorders (Arillotta et al., 2023; Tanday et al., 2022). These benefits are thought to arise, at least in part, from modulation of dopaminergic reward pathways and reductions in neuroinflammatory signaling (Mahapatra et al., 2022).Emerging evidence also points toward potential neuroprotective effects. GLP-1 signaling has been associated with reduced amyloid-ß accumulation, enhanced synaptic plasticity, and attenuation of neuroinflammatory processes implicated in Alzheimer’s disease (Behl et al., 2020; Kopp et al., 2022; Kong et al., 2023). Although clinical trial data remain limited, early findings suggest that GLP-1 agonists may help preserve cognitive performance—an observation of particular relevance given women’s disproportionate burden of dementia (Tanday et al., 2022).

 

3. Materials and Methods

3.1 Study Design

The present work was conducted as a narrative review with a specific focus on the role of GLP-1 receptor agonists in women’s health. Unlike systematic reviews, which typically follow rigid protocols for study selection and appraisal, narrative reviews are intentionally more flexible. They allow for the integration of diverse forms of evidence, the exploration of conceptual frameworks, and the synthesis of knowledge that spans multiple health domains. This design was deliberately selected to accommodate the expanding and interdisciplinary nature of GLP-1 research. In particular, it enabled the inclusion of clinical, preclinical, and translational studies relevant to muscle, bone, brain function, and functional longevity in women. (Sargeant et al., 2019)

3.2 Data Sources and Search Strategy

A comprehensive literature search was carried out using PubMed, Scopus, Web of Science, and Google Scholar to identify relevant publications published between 2015 and 2025. The search strategy incorporated combinations of key terms, including “GLP-1 receptor agonists,” “women’s health,” “muscle mass,” “bone density,” “cognition,” “longevity,” and “sex differences.” Boolean operators (AND/OR) were used to refine and combine search terms, as outlined in Table 1. To broaden coverage and minimize omissions, additional sources were identified through manual screening of reference lists from key review articles, as well as from clinical guidelines issued by professional organizations such as The Obesity Society and the American Diabetes Association.

Table 1: Search Strategy for Investigating GLP-1 Therapies on Women’s Muscle, Bone, Cognitive, and Longevity Outcomes. This table outlines the conceptual framework and keyword combinations used to systematically search the literature on GLP-1 receptor agonists or analogs in women. Concepts include interventions, population, and outcomes related to muscle, bone, cognition, and longevity/healthspan. Boolean operators (OR, AND) were applied to generate comprehensive search strings for database queries.

Concept Area

Keywords/Synonyms (combined with OR)

Example Combination with AND

Intervention

“GLP-1 receptor agonist” OR “GLP-1 analog” OR “Glucagon-like peptide-1 therapy”

 

Population

“Women” OR “Female” OR “Sex-specific” OR “Gender differences”

 

Muscle Outcomes

“Muscle mass” OR “Muscle strength” OR “Lean body mass” OR “Sarcopenia”

 

Bone Outcomes

“Bone density” OR “Bone health” OR “Bone mineral density” OR “Osteoporosis”

 

Cognitive Outcomes

“Cognition” OR “Cognitive function” OR “Neuroprotection” OR “Alzheimer’s disease”

 

Longevity/Healthspan

“Longevity” OR “Healthy aging” OR “Functional aging” OR “Healthspan”

 

Final Search String

(“GLP-1 receptor agonist” OR “GLP-1 analog”) AND (“Women” OR “Female”) AND (“Muscle strength” OR “Bone density” OR “Cognition” OR “Longevity”)

Example: (“GLP-1 receptor agonist” OR “GLP-1 analog”) AND (“Women” OR “Female”) AND (“Bone health” OR “Bone mineral density”)

3.3 Study Selection

Given the narrative nature of this review, study inclusion was guided primarily by relevance to women’s health and functional longevity rather than by strict eligibility thresholds. Both human and animal studies were considered when findings were judged to have clear translational implications. Priority was given to peer-reviewed articles, including clinical trials, observational studies, meta-analyses, expert consensus statements, and guideline documents. Materials excluded from consideration included conference abstracts, unpublished theses, editorials lacking original data, and studies not directly related to musculoskeletal, cognitive, or metabolic outcomes.

3.4 Data Extraction and Organization

Key information extracted from the included studies encompassed the following elements:
• Population characteristics, with emphasis on sex-specific data when available
• Study type, including clinical trials, observational studies, reviews, or guidelines
• Intervention details, such as the type and dosage of GLP-1 receptor agonist and duration of therapy
• Primary outcomes, including muscle mass and strength, bone mineral density, cognitive or neurological outcomes, and metabolic indicators
• Secondary outcomes, such as adverse effects, quality of life measures, or reported sex-specific differences

The extracted findings were subsequently organized thematically under three core domains central to functional longevity in women:
• Muscle health and strength
• Bone health and structural integrity
• Brain health and cognitive resilience

3.5 Data Synthesis

A descriptive, narrative synthesis approach was used to present the findings. Rather than relying on statistical pooling or quantitative meta-analysis, results were compared and contrasted across studies to identify areas of consistency, emerging patterns, and points of divergence. Particular attention was paid to sex-specific responses, with recognition that hormonal status and biological differences may meaningfully influence treatment outcomes in women.

3.6 Rationale for Narrative Approach

The decision to adopt a narrative review framework was intentional. Research on GLP-1 receptor agonists in women spans metabolic, musculoskeletal, and neurocognitive disciplines, resulting in substantial heterogeneity across study designs, populations, and outcome measures. Under these conditions, formal meta-analysis remains premature. A narrative approach, by contrast, allows for the integration of diverse insights while also critically highlighting conceptual gaps and areas requiring further investigation.

3.7 Ethical Considerations

As this study was based exclusively on previously published data, formal ethical approval was not required. Nonetheless, all sources were appropriately acknowledged, and care was taken to present findings in a balanced manner, avoiding selective reporting or overemphasis on isolated results.

4. Results and Discussion

4.1 Thematic Analysis

4.1.1 Theme 1: Muscle Health and Strength

One of the most striking themes that consistently pops up in the literature on GLP-1 receptor agonists is how they seem to affect skeletal muscle health. This is, I mean, really central to functional longevity in women. After all, muscle strength isn’t just about lifting things—it’s about independence, mobility, and maintaining quality of life, especially as women age or go through weight loss interventions. Evidence indicates that GLP-1 receptor agonists may actually help tweak muscle physiology in several ways—enhancing insulin sensitivity, improving mitochondrial function, and even dialing down inflammatory signaling (Wu et al., 2022). The bigger picture, including their effects on muscle, bone, brain, and overall metabolic health in women, is captured in Table 2. It’s fascinating, because these mechanisms could, in theory, shield muscle from catabolic loss and help preserve its quality (Figure 1).Yet, it’s not all straightforward. There’s this paradox where GLP-1 therapy, while effectively reducing fat, also tends to reduce lean body mass, with skeletal muscle making up roughly 15–30% of total weight lost (Tanday et al., 2022). This is tricky because the very metabolic benefits you get from losing weight might be partially offset by muscle loss, which can compromise strength and overall function. For women, who are already at higher risk of sarcopenia and osteoporosis later in life, this trade-off is particularly worrying (Schiellerup et al., 2019). It seems clear, then, that GLP-1 therapy can’t really be looked at in isolation; integrating it with resistance training, adequate protein, and other physical activity is probably critical to safeguard muscle while still reaping metabolic benefits (Love et al., 2020; Singh & Singh, 2022).

Figure 1. Forest Plot of Keyword Counts Across Concept Areas in GLP-1 Literature Search. This forest plot visualizes the number of keywords included for each concept area in the GLP-1 search strategy. Each point represents the mean keyword count for a concept, while the horizontal lines indicate the range of keywords considered. The “Final Search String” reflects the total keywords combined across all concepts, illustrating how individual domains contribute to the overall search strategy.

Table 2. Mechanisms and Key Outcomes of GLP-1 Therapies in Women Across Health Domains. This table summarizes the primary mechanisms of action, health outcomes, and supporting references for GLP-1 receptor agonists in women. It highlights effects on muscle, bone, brain, and metabolic health, including physiological pathways, clinical outcomes, and key literature evidence.

Health Domain

Mechanisms of Action

Key Outcomes in Women

Key References

Muscle health

Improved insulin sensitivity; reduced inflammation; enhanced mitochondrial efficiency

Preserved muscle quality; risk of lean mass loss during weight loss

Ahmed et al., 2023; Wu et al., 2022

Bone health

GLP-1 receptor activation in osteoblasts; reduced resorption

Modest increases in BMD; no increased fracture risk

Mabilleau et al., 2018; Xie et al., 2021

Brain health

Reduced neuroinflammation; modulation of amyloid-ß pathways

Improved cognitive resilience; potential neuroprotection

Behl et al., 2020; Kopp et al., 2022

Metabolic health

Enhanced insulin secretion; appetite regulation

Weight loss; improved glycemic control

Nauck & Meier, 2018; Tanday et al., 2022

4.1.2 Theme 2: Bone Health and Structural Integrity

Moving on to bone, the data from clinical trials generally suggest modest but measurable increases in bone turnover markers, alongside slight improvements in bone mineral density at sites like the lumbar spine and femoral neck. Interestingly, even with the significant weight loss associated with GLP-1 therapy, fracture risk doesn’t appear to rise, which implies that reductions in bone mass might be offset by improvements in bone quality. That’s particularly encouraging for women, since weight loss can otherwise accelerate bone loss in this population.Still, there are lingering concerns about the long-term skeletal impact. Weight loss itself is a known factor in reduced bone mineral density, and the protective bone effects of GLP-1 agonists might be muted by this process. Women who start with low bone density, vitamin D deficiency, or other osteoporosis risks remain vulnerable. So, the literature generally recommends combining GLP-1 therapy with lifestyle strategies—resistance or weight-bearing exercise, and sufficient calcium, protein, and vitamin D intake. Monitoring bone density over the long term is also advised to catch early changes. In short, GLP-1 receptor agonists appear to support bone health through both direct and indirect pathways, but careful balancing of benefits and risks is key, as summarized in Table 3.

Table 3. Benefits and Risks of GLP-1 Receptor Agonist Therapy in Women. This table summarizes the reported benefits, potential risks, and recommended mitigation strategies of GLP-1 receptor agonist therapy across key domains in women, including muscle, bone, brain, and longevity. It highlights both metabolic and functional effects while providing practical guidance to minimize adverse outcomes.

Domain

Reported Benefits

Potential Risks

Mitigation Strategies

Muscle

Improved insulin sensitivity; reduced inflammation

Lean mass loss (15–30% of weight loss)

Resistance training; adequate protein intake

Bone

Maintained BMD; stable fracture risk

Weight-loss-associated bone loss

Calcium, vitamin D, weight-bearing exercise

Brain

Appetite regulation; mood improvement; neuroprotection

Limited long-term sex-specific data

Long-term monitoring; cognitive screening

Longevity

Improved metabolic and functional healthspan

Hormonal variability in response

Personalized, sex-specific interventions

4.1.3 Theme 3: Brain Health and Cognitive Resilience

GLP-1 receptor agonists aren’t just about muscle and bone—they seem to influence the brain too. Appetite regulation, mood stabilization, and even cognitive resilience are areas where these therapies are increasingly recognized. GLP-1 receptors are spread throughout the central nervous system, including the hypothalamus, hippocampus, and brainstem, which allows these drugs to directly modulate neural activity. Appetite suppression via reduced hypothalamic signaling is a primary effect, and it seems to help curb cravings and emotional eating. Interestingly, these benefits happen somewhat independently of weight loss, supporting healthier eating habits and better adherence to lifestyle modifications (Arillotta et al., 2023).There’s also some promising evidence that GLP-1 therapy may have neuroprotective effects. Preclinical studies show reduced amyloid-ß accumulation, modulation of oxidative stress pathways, and improved synaptic plasticity—central factors in Alzheimer’s disease and related dementias. Clinical data, though still limited, hint at potential cognitive benefits, though long-term, sex-specific studies are needed to really confirm this. Notably, women are disproportionately affected by neurodegenerative disorders, making these findings particularly relevant. Overall, GLP-1 receptors seem to represent a convergence point where metabolic health, cognitive longevity, and emotional well-being intersect. This synthesis of preclinical, clinical, and guideline-based evidence is summarized in Table 4.

Table 4:  Evidence Supporting GLP-1 Receptor Agonists in Women’s Muscle, Bone, and Brain Health. This table summarizes the current evidence on GLP-1 receptor agonist therapy in women, integrating findings from preclinical studies, clinical trials, observational research, and expert reviews. It highlights key benefits for muscle, bone, and brain health while noting study limitations and gaps in long-term, female-specific data.

Evidence Type

Study Models

Primary Findings

Limitations

Preclinical studies

Animal and cellular models

Improved muscle metabolism; enhanced bone formation; neuroprotection

Limited translational data

Clinical trials

Obesity and T2DM populations

Weight loss; stable fracture risk; improved QoL

Lean mass loss; short follow-up

Observational studies

Women-focused cohorts

Sex-specific metabolic responses

Heterogeneity of outcomes

Reviews & guidelines

Expert consensus

Recommend combined lifestyle interventions

Limited long-term female-specific data

4.1.4 Theme 4: Integrated Functional Longevity

Bringing it all together, GLP-1 receptor agonists appear to act on multiple systems that contribute to functional longevity in women. Muscle, bone, brain, and metabolic networks are all influenced, often in overlapping ways. Yet, it’s clear that benefits come with nuances and potential trade-offs: lean mass reduction, bone considerations, and gaps in sex-specific research highlight the need for holistic and individualized approaches. Combining GLP-1 therapy with exercise, nutrition optimization, and careful monitoring is, therefore, not just recommended—it’s essential to maximize healthspan while mitigating unintended risks.

 

5. Conclusion

GLP-1 receptor agonists, it seems, provide benefits that extend well beyond simply managing weight or blood sugar. They appear to support muscle strength, help maintain bone integrity, and may even foster cognitive resilience—effects that together could meaningfully contribute to functional longevity in women. Yet, it’s also clear that challenges remain: therapy-associated lean mass loss, potential bone changes, and the still-limited sex-specific evidence cannot be overlooked. Thus, combining GLP-1 therapy with resistance and aerobic exercise, ensuring adequate protein, vitamin D, and calcium intake, and maintaining balanced nutrition becomes crucial for preserving musculoskeletal health. Regular monitoring of body composition and bone density is equally important, allowing for early detection of risks before they escalate. Looking forward, long-term, sex-specific studies are needed to refine personalized, holistic strategies that truly optimize women’s health and promote lasting independence

References


Ahmed, S., Naz, A., & K, M. (2023). Weight loss of over 100 lbs in a patient of Prader–Willi syndrome treated with glucagon-like peptide-1 (GLP-1) agonists. Cureus, 15(1), e35102. https://doi.org/10.7759/cureus.35102

Arillotta, D., Floresta, G., Guirguis, A., Corkery, J. M., Catalani, V., Martinotti, G., Sensi, S. L., & Schifano, F. (2023). GLP-1 receptor agonists and related mental health issues: Insights from a range of social media platforms using a mixed-methods approach. Brain Sciences, 13(11), 1503. https://doi.org/10.3390/brainsci13111503

Barrera, J. G., Sandoval, D. A., D’Alessio, D. A., & Seeley, R. J. (2011). GLP-1 and energy balance: An integrated model of short-term and long-term control. Nature Reviews Endocrinology, 7(9), 507–516. https://doi.org/10.1038/nrendo.2011.77

Behl, T., Kaur, I., Fratila, O., Brata, R., & Bungau, S. (2020). Exploring the potential of therapeutic agents targeted towards mitigating the events associated with amyloid-β cascade in Alzheimer’s disease. International Journal of Molecular Sciences, 21(20), 7443. https://doi.org/10.3390/ijms21207443

Konan, V., Swamy, N., Nisha, & Meghana. (2023). Endocrinology. The Journal of the Association of Physicians of India, 71(1), 79–86. https://doi.org/10.5005/jp/books/12622_8

Kong, F., Wu, T., Dai, J., Zhai, Z., Cai, J., Zhu, Z., Xu, Y., & Sun, T. (2023). Glucagon-like peptide-1 (GLP-1) receptor agonists in experimental Alzheimer’s disease models: A systematic review and meta-analysis of preclinical studies. Frontiers in Pharmacology, 14, 1205207. https://doi.org/10.3389/fphar.2023.1205207

Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022). Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. Pharmacological Research, 186, 106550. https://doi.org/10.1016/j.phrs.2022.106550

Lee, Y. S., & Jun, H. S. (2016). Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators of Inflammation, 2016, 3094642. https://doi.org/10.1155/2016/3094642

Love, K. M., Liu, J., Regensteiner, J. G., Reusch, J. E. B., & Liu, Z. (2020). GLP-1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes. Journal of Diabetes, 12(7), 534–546. https://doi.org/10.1111/1753-0407.13045

Mabilleau, G., Pereira, M., & Chenu, C. (2018). Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists. Journal of Endocrinology, 236(1), R29–R42. https://doi.org/10.1530/JOE-17-0278

Macedo, F., Romanatto, T., Gomes de Assis, C., Buis, A., Kowaltowski, A. J., Aguilaniu, H., & Marques da Cunha, F. (2020). Lifespan-extending interventions enhance lipid-supported mitochondrial respiration in Caenorhabditis elegans. FASEB Journal, 34(8), 10303–10316. https://doi.org/10.1096/fj.201901880R

Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022). Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis, and neurodegenerative diseases: A narrative review. Pharmaceutical Research, 39(6), 1341–1356. https://doi.org/10.1007/s11095-022-03302-1

Meng, J., Ma, X., Wang, N., Jia, M., Bi, L., Wang, Y., Li, M., Zhang, H., Xue, X., Hou, Z., Zhou, Y., Yu, Z., He, G., & Luo, X. (2016). Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through β-catenin. Stem Cell Reports, 6(4), 579–591. https://doi.org/10.1016/j.stemcr.2016.02.002

Nauck, M. A., & Meier, J. J. (2018). Incretin hormones: Their role in health and disease. Diabetes, Obesity and Metabolism, 20(Suppl. 1), 5–21. https://doi.org/10.1111/dom.13129

Ramracheya, R., Chapman, C., Chibalina, M., Dou, H., Miranda, C., González, A., Moritoh, Y., Shigeto, M., Zhang, Q., Braun, M., Clark, A., Johnson, P. R., Rorsman, P., & Briant, L. J. B. (2018). GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca²? channels. Physiological Reports, 6(17), e13852. https://doi.org/10.14814/phy2.13852

Reed, J., Bain, S., & Kanamarlapudi, V. (2021). A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives. Diabetes, Metabolic Syndrome and Obesity, 14, 3567–3602. https://doi.org/10.2147/DMSO.S319895

Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022). Sex differences in response to treatment with glucagon-like peptide-1 receptor agonists: Opportunities for a tailored approach to diabetes and obesity care. Journal of Personalized Medicine, 12(3), 454. https://doi.org/10.3390/jpm12030454

Richard, J. E., Anderberg, R. H., López-Ferreras, L., Olandersson, K., & Skibicka, K. P. (2016). Sex and estrogens alter the action of glucagon-like peptide-1 on reward. Biology of Sex Differences, 7(1), 6. https://doi.org/10.1186/s13293-016-0059-9

Sargeant, J. A., Henson, J., King, J. A., Yates, T., Khunti, K., & Davies, M. J. (2019). A review of the effects of glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter 2 inhibitors on lean body mass in humans. Endocrinology and Metabolism, 34(3), 247–262. https://doi.org/10.3803/EnM.2019.34.3.247

Schiellerup, S. P., Skov-Jeppesen, K., Windeløv, J. A., Svane, M. S., Holst, J. J., Hartmann, B., & Rosenkilde, M. M. (2019). Gut hormones and their effect on bone metabolism: Potential drug therapies in future osteoporosis treatment. Frontiers in Endocrinology, 10, 75. https://doi.org/10.3389/fendo.2019.00075

Singh, A. K., & Singh, R. (2022). Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. World Journal of Cardiology, 14(6), 329–343. https://doi.org/10.4330/wjc.v14.i6.329

Tanday, N., Flatt, P. R., & Irwin, N. (2022). Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands. British Journal of Pharmacology, 179(4), 709–728. https://doi.org/10.1111/bph.15485

Vilarrasa, E., Nicolau, J., de la Cueva, P., Goday, A., Gallardo, F., Martorell, A., & Carrascosa, J. M. (2024). Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases. Actas Dermo-Sifiliográficas, 115(1), 16–24. https://doi.org/10.1016/j.ad.2023.06.017

Wang, H., Hu, W., Xu, T., Yuan, Y., Liu, D., & Wüthrich, K. (2023). Selective polypeptide ligand binding to the extracellular surface of the transmembrane domains of the class B GPCRs GLP-1R and GCGR. iScience, 26(6), 106918. https://doi.org/10.1016/j.isci.2023.106918

Wu, L., Zhou, M., Li, T., Dong, N., Yi, L., Zhang, Q., & Mi, M. (2022). GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway. Biochimica et Biophysica Acta – Molecular Cell Research, 1869(9), 119300. https://doi.org/10.1016/j.bbamcr.2022.119300

Xie, B., Chen, S., Xu, Y., Han, W., Hu, R., Chen, M., Zhang, Y., & Ding, S. (2021). The impact of glucagon-like peptide-1 receptor agonists on bone metabolism and its possible mechanisms in osteoporosis treatment. Frontiers in Pharmacology, 12, 697442. https://doi.org/10.3389/fphar.2021.697442

 


Article metrics
View details
0
Downloads
0
Citations
25
Views

View Dimensions


View Plumx


View Altmetric



0
Save
0
Citation
25
View
0
Share